| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
NBD-X, SE targets primary amine groups on proteins, peptides, and other biomolecules. It forms covalent amide bonds with lysine residues and N-terminal amines, allowing fluorescent labeling of target molecules. The labeled molecules can then be detected by fluorescence microscopy, flow cytometry, or fluorescence spectroscopy.
|
|---|---|
| ln Vitro |
In vitro, NBD-X, SE is used to label proteins, peptides, and other amine-containing molecules. The labeled molecules are used in various biochemical assays, including protein-protein interaction studies, enzyme assays, and cellular imaging.
|
| ln Vivo |
In vivo, NBD-X, SE-labeled molecules may be used in imaging studies to track the distribution and dynamics of labeled biomolecules in living organisms. However, the compound itself is a labeling reagent rather than a therapeutic agent.
|
| Enzyme Assay |
The labeling protocol for NBD-X, SE involves incubating the compound with the target molecule (protein, peptide, or amine-containing compound) in a suitable buffer (e.g., phosphate buffer, pH 7.4) at room temperature for 1-2 hours. The reaction is typically performed in the dark to prevent photobleaching. The labeled product is purified by gel filtration or dialysis to remove excess unreacted dye. Labeling efficiency is assessed by measuring the absorbance or fluorescence of the labeled product.
|
| Cell Assay |
For in vitro cellular assays, NBD-X, SE-labeled molecules are added to cell cultures to study protein localization, trafficking, or interactions. Cells are incubated with the labeled molecule, and fluorescence is detected by microscopy or flow cytometry.
|
| Animal Protocol |
For in vivo imaging studies, NBD-X, SE-labeled molecules may be administered to animals, and fluorescence is detected using appropriate imaging systems.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for NBD-X, SE are not relevant, as it is a labeling reagent rather than a therapeutic agent.
|
| Toxicity/Toxicokinetics |
The toxicology of NBD-X, SE is primarily related to its use as a labeling reagent. At the low concentrations used for labeling, it is generally considered non-toxic. However, standard laboratory safety precautions should be followed.
|
| References | |
| Additional Infomation |
NBD-X, SE is a fluorescent labeling reagent used for labeling proteins, peptides, and other amine-containing molecules. It is a research tool for studying protein interactions, cellular localization, and biomolecular dynamics. The compound is not approved for human use and is intended for research purposes only.
|
| Molecular Formula |
C16H17N5O7
|
|---|---|
| Molecular Weight |
391.33548
|
| Exact Mass |
391.113
|
| CAS # |
145195-58-0
|
| PubChem CID |
10237523
|
| Appearance |
Yellow to brown solid powder
|
| Density |
1.51
|
| Boiling Point |
612.563ºC at 760 mmHg
|
| Flash Point |
324.267ºC
|
| LogP |
2.244
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
28
|
| Complexity |
609
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC(=O)N(C1=O)OC(=O)CCCCCNC2=CC=C(C3=NON=C23)[N+](=O)[O-]
|
| InChi Key |
ULIVORQJLJKPHQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H17N5O7/c22-12-7-8-13(23)20(12)27-14(24)4-2-1-3-9-17-10-5-6-11(21(25)26)16-15(10)18-28-19-16/h5-6,17H,1-4,7-9H2
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5553 mL | 12.7766 mL | 25.5532 mL | |
| 5 mM | 0.5111 mL | 2.5553 mL | 5.1106 mL | |
| 10 mM | 0.2555 mL | 1.2777 mL | 2.5553 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
